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Abstract 28 
An in silico approach was developed to predict the potential of 72 dietary proteins to act as 29 
a source of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides. The model takes 68 DPP-30 
IV inhibitory peptides (having an IC50 value < 2000 μM) and the specific contribution of their 31 
amino acids into account. Bovine α-lactalbumin (α-La) and κ-casein (CN) displayed the 32 
highest protein coverage (PC, 43.9 %) and potency index (PI, 17.9 10
-6
 μM-1 g-1), respectively 33 
for DPP-IV inhibitory peptides. Sequence alignment of 39 DPP-IV inhibitory peptides having 34 
IC50’s < 200 μM revealed the frequent occurrence of Trp at the N-terminus and Pro at 35 
position 2. Canola, chicken egg, oat and wheat were identified as potential sources of DPP-IV 36 
inhibitory peptides. In silico approaches may assist in the selection of food proteins for the 37 
enzymatic release of DPP-IV inhibitory peptides. The results are relevant to the generation of 38 
biofunctional ingredients for glycaemic management. 39 
 40 
Key words: dipeptidyl peptidase IV inhibitors, in silico model, bioactive peptides, food 41 
proteins, Type 2 diabetes. 42 
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1. Introduction 44 
Dipeptidyl peptidase IV (DPP-IV) is an ubiquitous enzyme which is involved in the 45 
cleavage of incretin hormones such as glucose dependent insulinotropic polypeptide (GIP) 46 
and glucagon-like peptide-1 (GLP-1). Following food intake, the incretins can modulate 47 
insulin synthesis and secretion (Juillerat-Jeanneret, 2014). Their cleavage results in a 48 
reduction in the circulating level of their active form, which in turn leads to a decrease in 49 
insulin secretion from pancreatic beta cells. DPP-IV inhibition is currently being used as a 50 
therapeutic strategy in the treatment of Type 2 diabetes (Juillerat-Jeanneret, 2014). Several 51 
DPP-IV inhibitory drugs, also known as gliptins, have been developed. These drugs generally 52 
have a high DPP-IV inhibitory potency, with half maximum inhibitory concentration (IC50) 53 
values of several nM (Nongonierma & FitzGerald, 2013b; Sortino, Sinagra & Canonico, 54 
2013). It has been shown that a wide range of dietary protein hydrolysates can inhibit DPP-IV 55 
(Connolly, Piggott & FitzGerald, 2014; Harnedy & FitzGerald, 2013; Hatanaka et al., 2012; 56 
Huang, Jao, Ho & Hsu, 2012; Li-Chan, Hunag, Jao, Ho & Hsu, 2012; Nongonierma & 57 
FitzGerald, 2013a; Uchida, Ohshiba & Mogami, 2011; Uenishi, Kabuki, Seto, Serizawa & 58 
Nakajima, 2012; Velarde-Salcedo et al., 2013). More particularly, milk protein hydrolysates 59 
have proven to be a good source of DPP-IV inhibitory peptides (Lacroix & Li-Chan, 2013; 60 
Lacroix & Li-Chan, 2014a; Nongonierma & FitzGerald, 2013a; Silveira, Martínez-Maqueda, 61 
Recio & Hernández-Ledesma, 2013; Tulipano, Sibilia, Caroli & Cocchi, 2011). Milk protein-62 
derived peptide sequences and free amino acids have been shown to possess a wide range of 63 
DPP-IV inhibitory potencies (Nongonierma & FitzGerald, 2013a, 2013c, 2013d, 2014; 64 
Nongonierma, Mooney, Shields & FitzGerald, 2013; Silveira et al., 2013; Tulipano et al., 65 
2011; Uchida et al., 2011; Uenishi et al., 2012). DDP-IV inhibitory peptide sequences 66 
originating from rice (Hatanaka et al., 2012), amaranth (Velarde-Salcedo et al., 2013), tuna 67 
cooking juice (Huang et al., 2012), a dried-cured ham water soluble extract (Gallego, Aristoy 68 
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& Toldrá, 2014), salmon (Li-Chan et al., 2012) and porcine skin gelatin (Hsu, Tung, Huang 69 
& Jao, 2013) have also been reported. However, milk appears to be the main dietary protein 70 
source from which DPP-IV inhibitory peptides have been identified to date. 71 
Different in silico approaches have been utilised to predict the potential of dietary proteins 72 
to act as a source of DPP-IV inhibitory peptides (Lacroix & Li-Chan, 2012). These studies 73 
have shown that proteins such as cow’s milk, bovine and salmon collagen (Lacroix & Li-74 
Chan, 2012; Udenigwe, Gong & Wu, 2013) and the small subunit of sorghum ribulose 75 
bisphosphate carboxylase (RuBisCo) (Udenigwe et al., 2013) were good sources of DPP-IV 76 
inhibitory peptide sequences. These in silico studies were based on calculation of the 77 
frequency of occurrence of DPP-IV inhibitory peptides which, corresponds to the number of 78 
DPP-IV inhibitory peptides found within a dietary protein divided by the protein length (total 79 
number of amino acid residues). These frequency of occurrence values, however, considered 80 
that all DPP-IV inhibitory peptide sequences may be simultaneously released from the 81 
relevant dietary protein and that they are equivalent in terms of their bioactive properties. 82 
However, neither the potency of the peptides nor the overlapping amino acid residues (≥ 1 83 
common amino acid residue) for the different DPP-IV inhibitory peptides were taken into 84 
account in these in silico analyses. Furthermore, new DPP-IV inhibitory peptide sequences 85 
have been discovered since the publication of these in silico studies (Lacroix & Li-Chan, 86 
2012; Udenigwe et al., 2013). The aim of this study was to develop an in silico methodology 87 
to predict the potential of various dietary proteins to act as precursors of DPP-IV inhibitory 88 
peptides. This in silico approach consisted of a model taking into account the potency of 89 
previously identified food protein-derived DPP-IV inhibitory peptides and also accounted for 90 
overlapping amino acid residues within a given protein region shared among different DPP-91 
IV inhibitory peptide sequences. The overall aim of this study was to develop a predictive 92 
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tool to assist in the choice of food protein substrate for the subsequent development of 93 
hydrolysates potentially containing potent DPP-IV inhibitory peptides. 94 
2. Materials and methods 95 
2.1. Food protein-derived DPP-IV inhibitory peptides 96 
Different DPP-IV inhibitory peptide sequences reported in the literature were considered 97 
for the in silico analysis. The DPP-IV inhibitory peptide sequences and their half maximal 98 
inhibitory concentration (IC50) values which were included in this study are summarised in 99 
Table 1. Food protein sequences which have previously been identified as a source of DPP-100 
IV inhibitory peptides using in vitro (Connolly et al., 2014; Harnedy & FitzGerald, 2013; 101 
Hatanaka et al., 2012; Huang et al., 2012; Lacroix & Li-Chan, 2014a, 2014b; Nongonierma & 102 
FitzGerald, 2013a; Silveira et al., 2013; Tulipano et al., 2011; Velarde-Salcedo et al., 2013), 103 
in silico (Lacroix & Li-Chan, 2012; Udenigwe et al., 2013) or in vivo (Uchida et al., 2011; 104 
Uenishi et al., 2012) approaches were considered in this study. Dietary proteins from plant 105 
and animal sources were analysed. The mature (without the propeptide) protein sequences 106 
(72) were obtained from UniProt using the ExPASy resource portal. The different proteins 107 
analysed in this study together with their accession number are listed in Table 2. 108 
The following rules were applied when assessing the potential of dietary proteins to act as 109 
a source of DPP-IV inhibitory peptides: 110 
- only peptides with an IC50 value < 2000 μM were taken into account in this study, other 111 
DPP-IV inhibitory peptides with higher IC50 values were not considered due to their 112 
relatively low in vitro potency. This cut off value was chosen since three amino acids (Trp, 113 
Met and Leu) have previously been shown to inhibit DPP-IV, however, their in vitro potency 114 
was low as they displayed IC50 values > 2000 μM (Nongonierma et al., 2013). 115 
- when specific peptide sequences have been reported with different IC50 values, the 116 
values reported in studies where the IC50 for Diprotin A (the positive control for the DPP-IV 117 
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inhibition assay) was between 3-5 μM (Huang et al., 2012; Nongonierma & FitzGerald, 118 
2013a; Silveira et al., 2013; Umezawa, Aoyagi, Ogawa, Naganawa, Hamada & Takeuchi, 119 
1984), were incorporated in the model. 120 
Peptide sequence alignment was carried out using the Matlab Bioinformatics tool box 121 
(version R2013b, MathWorks, Inc, Natick, MA, USA) for the 39 most potent DPP-IV 122 
inhibitory peptides, i.e., peptides with an IC50 value < 200 μM as listed in Table 1. In 123 
addition, sequence alignment of 58 peptides (Supplementary Table S1) with an IC50 > 2000 124 
μM or no DPP-IV inhibitory properties (Gallego et al., 2014; Hoffmann et al., 1995; 125 
Nongonierma & FitzGerald, 2013c, 2013d; Nongonierma et al., 2013; Silveira et al., 2013; 126 
Uenishi et al., 2012) was also carried out. Visualisation of sequence alignments was used to 127 
distinguish features in the primary sequence of the peptides which may be related to their 128 
DPP-IV inhibitory properties. Protein alignment for κ-casein (CN) from different species 129 
(bovine, human, ovine, caprine and bubaline) was also carried out to determine if the DPP-IV 130 
inhibitory peptides were present within conserved regions in this protein molecule. 131 
2.2. Identification of the presence of DPP-IV inhibitory peptides within different dietary 132 
proteins 133 
When a protein molecule is subjected to enzymatic hydrolysis, each amino acid residue 134 
therein can theoretically only contribute to one specific peptide. Therefore, when several 135 
DPP-IV inhibitory peptide sequences sharing at least one common amino acid residue have 136 
been reported within a given region of a specific dietary protein, only the most potent DPP-137 
IV inhibitory peptide was taken into account for its contribution to the overall DPP-IV 138 
inhibitory potential of that protein. The DPP-IV inhibitory peptide sequences sharing 139 
common amino residues in the 72 dietary proteins studied herein were identified using an in-140 
house algorithm developed with Matlab. 141 
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The corrected number of DPP-IV inhibitory peptides (ni,corrected) corresponded to the 142 
occurrence of a given peptide i (ni) less the occurrence of the most potent DPP-IV inhibitory 143 
peptide(s) sharing at least one common amino acid residue with peptide i. For example, 144 
within the peptides reported in Table 1, the motif Ile-Pro or Ile-Pro-Ile was common within 145 
the following peptides: Ile-Pro, Ile-Pro-Ala, Ile-Pro-Ala-Val-Phe, Ile-Pro-Ala-Val-Phe-Lys, 146 
Ile-Pro-Ile, Ile-Pro-Ile-Gln-Tyr and Leu-Pro-Gln-Asn-Ile-Pro-Pro-Leu. The peptides reported 147 
in Table 1 were mapped on the sequence of the individual milk proteins (Fig. 1). Considering 148 
bovine κ-CN by the way of example (Fig. 1), the peptides present within this protein from the 149 
above list are Ile-Pro (κ-CN f(26-27), κ-CN f(108-109) and κ-CN f(119-120)), Ile-Pro-Ile (κ-150 
CN f(26-28)) and Ile-Pro-Ile-Tyr-Gln (κ-CN f(26-30)). The region within bovine κ-CN f(26-151 
30) contains 3 overlapping DPP-IV inhibitory peptides, with the following potency: Ile-Pro-152 
Ile (IC50 3.5 μM) > Ile-Pro-Ile-Gln-Tyr (IC50 35.2 μM) > Ile-Pro (IC50 149.6 μM). Therefore, 153 
in order to generate a DPP-IV inhibitory potency index (PI, section 2.4.) for κ-CN, one Ile-154 
Pro-Ile (κ-CN f(26-28)) and two Ile-Pro (κ-CN f(108-109) and κ-CN f(119-120)) sequences 155 
were considered in the in silico model whereas Ile-Pro-Ile-Gln-Tyr was not included. This 156 
selection process was enacted in order to avoid considering the contribution of the same 157 
amino acid residue or partial peptide sequence to the overall DPP-IV inhibitory properties 158 
more than once during the in silico analysis. 159 
2.3. Determination of a protein coverage (PC) value 160 
The proportion of amino acid residues participating in DPP-IV inhibitory peptide 161 
sequences with IC50 values < 2000 μM (Table 1) within each dietary protein was calculated 162 
to provide a PC value. This was determined using the Protein Coverage Summarizer 163 
("http://omics.pnl.gov/software/ProteinCoverageSummarizer.php,"). 164 
The corrected PC (PCcorrected) only took into account the most potent DPP-IV inhibitory 165 
peptide in overlapping areas of the protein sequence. The PCcorrected of DPP-IV inhibitory 166 
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peptide sequences within each dietary protein was calculated as follows using an in house 167 
Matlab program:  168 
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Where xi is the length of the DPP-IV inhibitory peptide i (number of amino acid 170 
residues); 171 
  ni,corrected is the corrected occurrence of peptide i in the dietary protein;  172 
Y is the length (total number of amino acid residues) of the mature protein 173 
(i.e., without the propeptide sequence). 174 
 175 
When PCcorrected was equal to PC, this indicated that there were no overlapping DPP-IV 176 
inhibitory peptides within the protein sequence. 177 
2.4. Determination of the DPP-IV inhibitory potency index (PI) 178 
A DPP-IV inhibitory PI was calculated for different proteins taking into account the 179 
potency (IC50 value) of the DPP-IV inhibitory peptides evaluated therein using Matlab. The 180 
PI (expressed in μM-1 g-1) of each protein was calculated using the following formula: 181 
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Where IC50,i is the half maximal inhibitory concentration of peptide i (μM); 183 
ni,corrected is the corrected occurrence of peptide i in one mole of protein; 184 
MW is the molecular mass of the protein (g mol
-1
). 185 
 186 
The PI therefore takes into account both the occurrence and potency (IC50) of the peptides 187 
present within a given protein. The PI is proportional to the corrected occurrence (ni,corrected) 188 
and the reciprocal of the IC50 value of the DPP-IV inhibitory peptides. Therefore, the higher 189 
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the PI value for a given dietary protein, the more likely it is to contain a high number of 190 
and/or potent DPP-IV inhibitory peptides. 191 
3. Results 192 
3.1. DPP-IV inhibitory peptides selected for the in silico analysis 193 
A list of 68 DPP-IV inhibitory peptides with an IC50 value < 2000 μM was compiled from 194 
the literature (Table 1). These sequences included Diprotin A and B (Umezawa et al., 1984) 195 
and DPP-IV inhibitory peptides which have previously been identified in the sequences of a 196 
wide range of food proteins including milk (Lacroix & Li-Chan, 2014a; Nongonierma & 197 
FitzGerald, 2013a, 2013c, 2013d, 2014; Silveira et al., 2013; Tulipano et al., 2011; Uchida et 198 
al., 2011; Uenishi et al., 2012), rice (Hatanaka et al., 2012), tuna cooking juice (Huang et al., 199 
2012) along with porcine (Hsu et al., 2013) and salmon skin gelatin (Li-Chan et al., 2012). 200 
In certain instances, different IC50 values have been reported for the same peptide. This 201 
was the case for Ile-Pro-Ile, Ile-Pro and Leu-Pro, which were reported to have IC50 values of 202 
210, 410 and 2370 μM, respectively, in the study of Hatanaka et al. (2012). However, these 203 
values were not taken into account in the in silico analysis herein since lower values were 204 
described in another study (Nongonierma & FitzGerald, 2014), where the IC50 for the 205 
positive control Ile-Pro-Ile was in agreement with or was of the same order as that reported 206 
elsewhere (Huang et al., 2012; Silveira et al., 2013; Umezawa et al., 1984). 207 
The peptides displayed a wide range of IC50 values, from 3.5 to 1691.4 μM for Ile-Pro-Ile 208 
and Met-Trp, respectively. Some of the DPP-IV inhibitory peptides selected herein share 209 
common amino acid residues. Therefore, overlapping amino acids in dietary proteins were 210 
considered in order to only take these sequences into account once in the in silico analysis. 211 
This was done to account for the fact that for each mole of dietary protein, each amino acid 212 
can only be part of a single DPP-IV inhibitory peptide. 213 
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Peptide sequence alignment for the 39 most potent (IC50 < 200 μM) DPP-IV inhibitory 214 
peptides is illustrated in Fig. 2a. These DPP-IV inhibitory peptide sequences were ordered by 215 
decreasing potency (increasing IC50 value). The consensus in the primary sequence of the 216 
DPP-IV inhibitory peptides with IC50 values < 200 μM was determined to be a Trp at the N 217 
terminus and a Pro at position 2. Peptide sequences with an IC50 > 2000 μM or no DPP-IV 218 
inhibitory properties (Fig. 2b) did not possess the same features as those DPP-IV inhibitory 219 
peptides with IC50 values < 200 μM. 220 
3.2. Occurrence of DPP-IV inhibitory peptides in dietary proteins 221 
To date, most of the DPP-IV inhibitory peptides identified from dietary protein sources 222 
come from milk proteins (Table 1). However, this is probably related to the fact that most 223 
research on dietary protein hydrolysates with DPP-IV inhibitory properties has been carried 224 
out with milk proteins. This analysis showed that all the individual milk proteins contain 225 
multiple peptide sequences with DPP-IV inhibitory properties. Furthermore, the DPP-IV 226 
inhibitory peptides appear to be randomly distributed throughout the primary sequence of the 227 
different milk proteins. Within milk proteins, the PC and the PCcorrected with DPP-IV 228 
inhibitory peptides with an IC50 < 2000 μM ranged from 7.9 to 43.9 % for bovine serum 229 
albumin (BSA) and α-La, respectively (Table 2). 230 
Specific peptide sequences which have previously been identified in milk proteins may 231 
also be found in other dietary protein sources. This may be the case, in particular, for short 232 
peptide sequences (di-, tri- and tetrapeptides). Therefore, the in silico approach described 233 
herein was applied to a wide range of dietary proteins. The occurrence of DPP-IV inhibitory 234 
peptides in the different dietary proteins was evaluated with the PC and the PCcorrected analysis 235 
(Table 2). The PC described the proportion of the protein consisting of DPP-IV inhibitory 236 
peptides with an IC50 < 2000 μM. Whereas PCcorrected only considered the most potent DPP-237 
IV inhibitory peptide in overlapping areas of the protein sequence. Among the proteins listed 238 
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in Table 2, the highest PC was estimated for bovine α-La (43.9 %) and the lowest for bovine 239 
myosin regulatory light chain 12B (1.2 %). The highest and lowest PCcorrected values were also 240 
found for the same proteins. Different numbers of unique sequences with DPP-IV inhibitory 241 
activity were taken into account in the in silico model (Table 2). The highest being for bovine 242 
lactoferrin (18 peptides) and Atlantic salmon collagen Type XI α2 (18 peptides) and the 243 
lowest being for bovine myosin regulatory light chain 12B (1 peptide). 244 
3.3. DPP-IV inhibitory PI of dietary proteins 245 
The DPP-IV inhibitory PI was calculated for each dietary protein (Table 2). The highest 246 
value for the PI was found for bovine κ-CN (17.89 10-6 μM-1 g-1) and the lowest for bovine 247 
myosin regulatory light chain 12B and chicken egg ovomucoid (0.13 10
-6
 μM-1 g-1). Most 248 
dietary proteins (90 %) had a PI < 5.00 10
-6
 μM-1 g-1. Proteins with a PI > 5.00 10-6 μM-1 g-1 249 
included bovine milk (κ-CN and α-La), canola (napin small chain), Palmaria palmata 250 
(allophycocyanin α chain and phycoerythrin β subunit), chum salmon (type 1 collagen α2 251 
chain), chicken egg (ovotransferrin), oat (avenin) and wheat (glutenin, low molecular weight 252 
subunit 1D1) proteins. 253 
The PC was equal to the PCcorrected for 23 of the dietary proteins studied (Table 2). When 254 
the PC equals PCcorrected, the protein does not present any overlapping DPP-IV inhibitory 255 
peptides in its primary sequence. When PCcorrected < PC, this indicates that the protein 256 
contained overlapping DPP-IV inhibitory peptides. The difference between PCcorrected and the 257 
PC was the highest with bovine α-La, β-lactoglobulin (β-Lg), β- and κ-CN, with a difference 258 
> 15%. 259 
Bovine κ-CN had the highest PI, therefore, the in silico analysis was also applied to κ-CN 260 
from different species including human, ovine, caprine and bubaline sources (Table 3). The 261 
PI for ovine κ-CN was the highest (18.52 10-6 μM-1 g-1) and the lowest was for human κ-CN 262 
(2.11 10
-6
 μM-1 g-1). These variations in the PI between species arise from the DPP-IV 263 
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inhibitory peptide sequences found within the different κ-CNs. In addition, ovine κ-CN 264 
contained the highest number (11) of DPP-IV inhibitory peptides with an IC50 < 2000 μM 265 
while human κ-CN contained the lowest (6). Ovine κ-CN contained 2 highly potent (< 50 266 
μM) DPP-IV inhibitors, Ile-Pro-Ile and Ile-Pro-Ala (IC50 3.5 and 49 μM, respectively). 267 
Interestingly, human κ-CN was the only κ-CN which does not contain Ile-Pro-Ile, Leu-Pro-268 
Tyr-Pro-Tyr, Trp-Gln and His-Leu. 269 
Protein alignment of κ-CN from the different species was carried out (Fig. 3) to assess if 270 
the DPP-IV inhibitory peptides belong to conserved regions within the molecule. The regions 271 
containing DPP-IV inhibitory peptides with IC50 < 200 μM are highlighted on Fig. 3. Most 272 
sequences were found within non-conserved protein domains. This was the case for the 2 273 
most potent DPP-IV inhibitors identified within κ-CN (Ile-Pro-Ile and Ile-Pro-Ala). However, 274 
three peptide sequences (Tyr-Pro, Val-Arg and Ile-Pro) with a low DPP-IV inhibitory 275 
potency were found within conserved domains for all 5 species. 276 
4. Discussion 277 
Various studies have highlighted the potential of food protein-derived peptides to act as 278 
antidiabetic components (Lacroix & Li-Chan, 2014b). In this context, inhibition of DPP-IV 279 
by food protein-derived peptides has been suggested as an avenue for the regulation of serum 280 
glucose in vivo (Uchida et al., 2011; Uenishi et al., 2012). Numerous peptide sequences 281 
having DPP-IV inhibitory properties have been reported in the literature. However, it is still 282 
not clear which structural/compositional parameters correlate with potent DPP-IV inhibitory 283 
properties. Peptide length does not appear to govern DPP-IV inhibition as large peptides (> 284 
10 amino acid residues) have been shown to be DPP-IV inhibitors (Velarde-Salcedo et al., 285 
2013). Some of these peptides were relatively potent (IC50 value < 100 μM) DPP-IV 286 
inhibitors (Huang et al., 2012; Lacroix & Li-Chan, 2014a; Uenishi et al., 2012). Amino acid 287 
composition is also not the primary component which would appear to govern DPP-IV 288 
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inhibitory properties as demonstrated by the differences in activity between reverse and 289 
forward dipeptides (Hatanaka et al., 2012; Nongonierma & FitzGerald, 2013a, 2013d). 290 
Alignment of 39 relatively potent DPP-IV inhibitory peptides (IC50 < 200 μM) showed 291 
that the presence of a Trp at the N terminal and a Pro at position 2 was correlated with good 292 
inhibitory properties. This result arises from the fact that many peptides which have been 293 
identified as potent DPP-IV inhibitors (Fig. 2) possess a Trp at their N terminus (10 peptides) 294 
or a Pro at position 2 (17 peptides). Previous dipeptide studies have shown that a N-terminal 295 
Trp residue was generally associated with low DPP-IV IC50 values as opposed to the 296 
associated reverse peptide (Nongonierma & FitzGerald, 2013d). Similarly, the presence of 297 
Pro at position 2 (Nongonierma & FitzGerald, 2014) and at the C-terminus (Nongonierma & 298 
FitzGerald, 2013c) of peptides has been shown, in certain instances, to yield relatively potent 299 
DPP-IV inhibitory peptides. Hikida, Ito, Motoyama, Kato & Kawarasaki (2012) have taken a 300 
systematic approach to study dipeptides for their ability to inhibit human DPP-IV. They 301 
reported that Trp-Pro and Trp-Arg yielded the highest inhibition constants (Ki) of the 302 
dipeptides analysed. This is in agreement with previous results showing that Trp-Pro had an 303 
IC50 value of 44.5 μM which, similarly to Trp-Arg, Trp-Lys and Trp-Leu, was one of the 304 
most potent for the Trp-containing dipeptides tested (Nongonierma & FitzGerald, 2013d). 305 
Peptides with weak or no DPP-IV inhibition generally had a different sequence, which 306 
appears to indicate that specific features in the peptide sequence may correlate with their 307 
biological activity. Previous studies have utilised molecular docking approaches to better 308 
understand the mechanisms of DPP-IV inhibition by food protein-derived peptides 309 
(Nongonierma et al., 2013; Velarde-Salcedo et al., 2013). To our understanding, this is the 310 
first time that a peptide alignment strategy has been used to elucidate the relationship 311 
between the peptide sequence and DPP-IV inhibitory pproperties. 312 
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The DPP-IV inhibitory PI was introduced to prioritise the most potent DPP-IV inhibitory 313 
peptides in regions of dietary proteins containing overlapping DPP-IV inhibitory peptides. In 314 
silico predictive approaches up to now (Lacroix & Li-Chan, 2012; Udenigwe et al., 2013) 315 
considered all DPP-IV inhibitory peptides regardless of their potency and overlap with other 316 
DPP-IV inhibitory peptides in the primary sequence of the same protein. Lacroix & Li-Chan 317 
(2012) and Udenigwe et al. (2013) reported that bovine β-CN had the highest frequency of 318 
occurrence of DPP-IV inhibitory peptides (0.249 and 0.148, respectively) of the dietary 319 
proteins they included in their in silico analysis. In contrast to earlier results (Lacroix & Li-320 
Chan, 2012; Udenigwe et al., 2013) which described bovine β-CN as the milk protein 321 
substrate with the highest potential for DPP-IV inhibitory peptides, our in silico analysis 322 
concluded that bovine α-La displayed the highest PC (43.9 %) and that bovine κ-CN was the 323 
protein with the highest PI. The peptide sequences found within bovine κ-CN were more 324 
potent DPP-IV inhibitory peptides, in particular, the Ile-Pro-Ile sequence. Discrepancies 325 
between the outcomes of the in silico analysis herein and previous studies arise from the fact 326 
that the PI analysis allows to quantitatively assess the potential of a protein to act as a source 327 
of DPP-IV inhibitory peptides. In contrast, other parameters such as the PC and the frequency 328 
of occurrence are rather qualitative. 329 
Alignment of the DPP-IV inhibitory peptide sequences of κ-CN from various species 330 
showed that the peptides were not generally located in conserved regions of the protein. 331 
Interestingly, it was found that ovine κ-CN had the highest PI. In contrast, human κ-CN had a 332 
surprisingly low index (~ 9 times lower than that of ovine κ-CN). A recent study has shown 333 
that at equivalent lactose content, a human milk meal was less insulinogenic than a bovine 334 
milk meal when ingested by humans (Gunnerud, Holst, Östman & Björck, 2012). However, 335 
in this study, the human milk sample was tested at a lower protein level compared to the 336 
bovine milk (3.5 and 16.8 g, respectively). Major differences between animal and human 337 
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milk exists in terms of their carbohydrate composition, notably, human milk contains nearly 338 
twice as much lactose (7.5 g L
-1
) as bovine, caprine and bubaline milk (Fox, 2009). The high 339 
lactose levels in human milk may help to counteract damage to vital organs of the neonate, 340 
which may occur in the event of prolonged hypoglycaemia, a condition which is often 341 
encountered with neonates (Adamkin, 2011). The high lactose content of human milk may 342 
induce an increased insulin secretion in the post prandial phase. Therefore, it could be 343 
hypothetised that regulation of insulin secretion through DPP-IV inhibition may not be as 344 
critical with humans as compared with other species. This may explain the low PI of human 345 
κ-CN compared to that of bovine, ovine and bubaline milk. 346 
With the exception of porcine gelatin, it was found that several proteins (barley, rice, 347 
amaranth, salmon, pig and Palmaria palamata) which were previously identified as dietary 348 
sources of DPP-IV inhibitory peptides had a PI value > 4.00 10
-6
 μM-1 g-1 (Table 2). Since the 349 
primary sequence of porcine gelatin and salmon collagen are currently not available, their PI 350 
could not be determined. The low PI for the other porcine proteins is consistent with the fact 351 
that the IC50 values of the peptides identified in cooking juice of dry cured ham were quite 352 
high (several mM) (Gallego et al., 2014). Other dietary proteins, which have not been 353 
experimentally evaluated to date for their DPP-IV inhibitory properties, had a high PI value 354 
(> 5.00 10
-6
 μM-1 g-1). These include canola (napin small chain), chicken egg 355 
(ovotransferrin), oat (avenin) and wheat (glutenin low molecular weight subunit 1D1). 356 
 357 
The main limitation of the in silico approach presented herein is the fact that it is based on 358 
current knowledge of the potency of DPP-IV inhibitory peptide sequences. For this reason, 359 
the model does not take into account other potential DPP-IV inhibitory peptides which are yet 360 
to be discovered or characterised. However other in silico approaches currently suffer from 361 
the same fate. The model is also based on the IC50 values reported in the literature. However, 362 
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different experimental protocols have been employed to determine these values (Table 1). 363 
The DPP-IV inhibition assay is affected by different parameters including the source of the 364 
DPP-IV employed, its purity, enzyme activity, the synthetic substrate used, the temperature 365 
and the enzyme to substrate ratio employed during the assay. Therefore, it is difficult to try to 366 
standardise different values reported in the literature. In addition, the model is based on the 367 
assumption that the most potent DPP-IV inhibitory peptide will be released from regions 368 
containing overlapping peptide sequences. It may therefore lead to an overestimation of the 369 
potential of a protein to act as a good starting substrate for DPP-IV inhibitory peptides. 370 
However, the model is flexible and can build in discoveries of novel DPP-IV inhibitory 371 
peptides or take into consideration the worst case scenario whereby the least potent peptide 372 
would be released from protein regions containing overlapping DPP-IV inhibitory peptides. 373 
This in silico approach could be considered as a starting point to identify dietary proteins 374 
which are enriched in potent DPP-IV inhibitory peptides. To date, other in silico approaches 375 
aiming to identify dietary proteins enriched in DPP-IV inhibitory peptides have not taken into 376 
account the potency of previously identified DPP-IV inhibitory peptides and have considered 377 
that the same amino acid from a dietary protein could participate in several DPP-IV 378 
inhibitory peptide sequences. Evaluation of the DPP-IV inhibitory properties of enzymatic 379 
hydrolysates of proteins predicted to have a high PI is needed in order to validate the model 380 
presented herein. Ultimately, the peptides released will be governed by the nature of the 381 
enzymatic preparation and the hydrolysis conditions employed during protein hydrolysis. 382 
Conclusion 383 
An in silico approach to evaluate the DPP-IV inhibitory potential of dietary proteins has 384 
been developed. This model allowed for the identification of new dietary proteins which 385 
contain potent DPP-IV inhibitory peptides. It takes into account both the potency of DPP-IV 386 
inhibitory peptides and the fact that each amino acid from a dietary protein can only 387 
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participate once in a DPP-IV inhibitory peptide sequence. The model also incorporates the 388 
latest DPP-IV inhibitory peptide sequences which have been discovered since previous in 389 
silico studies in the area. In addition, peptide alignment approach was used herein to allow 390 
for a better understanding of those features which are shared among relatively potent DPP-IV 391 
inhibitory peptides (IC50 < 200 μM). However the data presented herein needs to be validated 392 
with in vitro enzymatic digestion of the individual substrates identified and the stability of the 393 
peptides to gastrointestinal digestion also needs to be assessed. This work has highlighted a 394 
new approach to predict the DPP-IV inhibitory potential of food protein-derived peptides and 395 
to assess the potential of dietary proteins as a source for potent DPP-IV inhibitory peptides. 396 
The strategy described herein could also be applied more broadly to other bioactive peptides 397 
of relevance to human health. 398 
399 
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Table 1 Dipeptidyl peptidase IV (DPP-IV) inhibitory peptide sequences used in the in silico study together with their half maximal inhibitory concentration (IC50). Peptide 
sequences are ordered by decreasing potency (increasing IC50 value). 
 
Peptide sequence* IC50 (μM)** 
Peptide length Conditions used for the DPP-IV 
inhibitory assay
†
 
Source 
IPI 3.5 3 
37C, pH 8, 60 min with the 
synthetic substrate Gly-Pro-pNA 
(0.2 mM) using 2.5 mU mL
-1
 of 
DPP-IV 
(Nongonierma & FitzGerald, 2014) 
VPL 15.8 3 
37C, pH 7.2, 30 min with the 
synthetic substrate Gly-Pro-pNA 
(0.4 mM) DPP-IV units not 
disclosed 
(Umezawa, et al., 1984) 
IPIQY 35.2 5 - (Nongonierma & FitzGerald, 2014) 
WR 37.8 2 
37C, pH 8, 60 min with the 
synthetic substrate Gly-Pro-pNA 
(0.2 mM) using 2.5 mU mL
-1
 of 
DPP-IV 
(Nongonierma & FitzGerald, 
2013d) 
WK 40.6 2 - 
(Nongonierma & FitzGerald, 
2013d) 
GPAG 41.1 4 
37C, pH 8, 60 min with the 
synthetic substrate Gly-Pro-pNA 
(0.4 mM) using 50 mU mL
-1
 of 
DPP-IV 
(Hsu, et al., 2013) 
GPGA 41.9 4 
37C, pH 8, 60 min with the 
synthetic substrate Gly-Pro-pNA 
(0.4 mM) using 50 mU mL
-1
 of 
DPP-IV 
(Li-Chan, et al., 2012) 
WL 43.6 2 - 
(Nongonierma & FitzGerald, 
2013d) 
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WP 44.5 2 - 
(Nongonierma & FitzGerald, 
2013d) 
IPAVF 44.7 5 
37C, 30 min (pH not disclosed) 
with the synthetic substrate Gly-
Pro-pNA (0.1 mM) using 2.6 mU 
mL
-1
 of DPP-IV 
(Silveira, et al., 2013) 
LKPTPEGDL 45 9 
37C, pH 8, 60 min with the 
synthetic substrate Gly-Pro-pNA 
(0.4 mM) using 50 mU mL
-1
 of 
DPP-IV 
(Lacroix & Li-Chan, 2014a) 
LPQNIPPL 46 8 
Room temperature, pH 8, 45 min 
with the synthetic substrate Gly-
Pro-aminoluciferin (DPPIV-Glo™ 
Protease Assay, Promega) using 
0.11 mU mL
-1
 of DPP-IV 
(Uenishi, et al., 2012) 
IPA 49 3 
37C, pH 8, 45 min with the 
synthetic substrate Gly-Pro-pNA 
(0.1 mM) using 2.6 mU mL
-1
 of 
DPP-IV 
(Tulipano, et al., 2011) 
GPAE 49.6 4 - (Li-Chan, et al., 2012) 
LKPTPEGDLEIL 57 12 - (Lacroix & Li-Chan, 2014a) 
FLQP 65.3 4 
37C, pH 8, 60 min with the 
synthetic substrate Gly-Pro-pNA 
(0.2 mM) using 2.5 mU mL
-1
 of 
DPP-IV 
(Nongonierma & FitzGerald, 
2013c) 
WV 65.7 2 
37C, pH 8, 60 min with the 
synthetic substrate Gly-Pro-pNA 
(0.2 mM) using 2.5 mU mL
-1
 of 
DPP-IV 
(Nongonierma & FitzGerald, 
2013a) 
CAYQWQRPVDRIR 78 13 
37C, pH 8, 60 min with the 
synthetic substrate Gly-Pro-pNA 
(0.4 mM) using 50 mU mL
-1
 of 
(Huang, et al., 2012) 
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DPP-IV 
LPQ 82 3 - (Uenishi, et al., 2012) 
WA 92.6 2 - 
(Nongonierma & FitzGerald, 
2013d) 
PACGGFWISGRPG 96.4 13 - (Huang, et al., 2012) 
LPYPY 108.3 5 - (Nongonierma & FitzGerald, 2014) 
VPITPTL 110 7 - (Uenishi, et al., 2012) 
PGVGGPLGPIGPCYE 116.1 15 - (Huang, et al., 2012) 
WQ 120.3 2 - 
(Nongonierma & FitzGerald, 
2013d) 
VPITPT 130 6 - (Uenishi, et al., 2012) 
WI 138.7 2 - 
(Nongonierma & FitzGerald, 
2013d) 
WLAHKALCSEKLDQ 141 14 - (Lacroix & Li-Chan, 2014a) 
IPAVFK 143 6 - (Silveira, et al., 2013) 
HL 143.2 2 - 
(Nongonierma & FitzGerald, 
2013a) 
WN 148.5 2 - 
(Nongonierma & FitzGerald, 
2013d) 
IP 149.6 2 - (Nongonierma & FitzGerald, 2014) 
LAHKALCSEKL 165 11 - (Lacroix & Li-Chan, 2014a) 
TKCEVFRE 166 8 - (Lacroix & Li-Chan, 2014a) 
VA 168.2 2 - 
(Nongonierma & FitzGerald, 
2013a) 
VAGTWY 174 6 
37C, pH 8, 30 min with the 
synthetic substrate Gly-Pro-pNA 
(0.5 mM) DPP-IV units not 
disclosed 
(Uchida, et al., 2011) 
YPYY 194.4 4 - (Nongonierma & FitzGerald, 2014) 
WIQP 237.3 4 - (Nongonierma & FitzGerald, 2014) 
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LPL 241.4 3 - (Nongonierma & FitzGerald, 2014) 
WM 243.1 
2 - (Nongonierma & FitzGerald, 
2013d) 
YPY 243.7 3 - (Nongonierma & FitzGerald, 2014)
 
ILDKVGINY 263 9 - (Lacroix & Li-Chan, 2014a) 
WY 281 
2 - (Nongonierma & FitzGerald, 
2013d) 
WLAHKAL 286 7 - (Lacroix & Li-Chan, 2014a) 
TPEVDDEALEK 319.5 11 - (Silveira, et al., 2013) 
LPLPL 325 5 - (Nongonierma & FitzGerald, 2014) 
IVQNNDSTEYGLF 337 13 - (Lacroix & Li-Chan, 2014a) 
FL 399.6 
2 - (Nongonierma & FitzGerald, 
2013a) 
WC 420 
2 - (Nongonierma & FitzGerald, 
2013d) 
VLVLDTDYK 424.4 
9 - (Nongonierma & FitzGerald, 
2013a) 
WT 482.1 
2 - (Nongonierma & FitzGerald, 
2013d) 
WW 554.8 
2 - (Nongonierma & FitzGerald, 
2013d) 
VLGP 580.4 
4 - (Nongonierma & FitzGerald, 
2013c) 
WS 643.5 
2 - (Nongonierma & FitzGerald, 
2013d) 
YP 658.1 2 - (Nongonierma & FitzGerald, 2014) 
YPFPGPIPN 670 9 - (Uenishi, et al., 2012) 
LP 712.5 2 - (Nongonierma & FitzGerald, 2014) 
VR 826.1 
2 - (Nongonierma & FitzGerald, 
2013c) 
MP 870 2 37C, pH 7.5, with the synthetic (Hatanaka, et al., 2012) 
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substrate Ala-Pro-pNA (0.2 mM) 
using 30 mU mL
-1
 of DPP-IV 
VP 880 2 - (Hatanaka, et al., 2012) 
AL 882.1 
2 - (Nongonierma & FitzGerald, 
2013a) 
LW 993.4 
2 - (Nongonierma & FitzGerald, 
2013d) 
PGPIHNS 1000 7 - (Uenishi, et al., 2012) 
LQP 1181.1 
3 - (Nongonierma & FitzGerald, 
2013c) 
IPPLTQTPV 1300 9 - (Silveira, et al., 2013)
 
MW 1691.4 
2 - (Nongonierma & FitzGerald, 
2013d)
 
*Peptide sequence using the one letter amino acid code 
**Peptides are ordered by increasing IC50 values 
†The conditions used for the DPP-IV inhibitory assay are reported at the first mention for each bibliographic reference. 
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Table 2 Predictive dipeptidyl peptidase IV (DPP-IV) inhibitory potential of various dietary proteins. Different values determined by the in silico predictive approach include 
the protein coverage (PC), corrected number of peptides taken into account in the in silico model, the corrected PC (PCcorrected) taking into account the peptides considered in 
the in silico model and the DPP-IV inhibitory potency index (PI). 
 
Protein origin Protein name 
Accession 
number
†
 
PC (%)
‡
 
Number of 
peptide 
sequences
*
 
PCcorrected
**
 
(%) 
PI
#
  
(μM-1 mol-1) 
×10
6
 
(μM-1 g-1) 
Wheat (Triticum 
aestivum) 
α/ β-gliadin P02863 15.8 12 15.8 0.127 4.13 
 
Glutenin, high molecular weight 
subunit 12 
P08488 10.2 9 10.2 0.102 1.49 
 
Glutenin, low molecular weight 
subunit 1D1 
P10386 14.8 11 14.8 0.168 5.17 
 Large subunit RuBisCO P11383 9.9 12 9.7 0.133 2.53 
 Small subunit RuBisCO P26667 15.6 8 14.1 0.071 4.77 
Barley (Hordeum 
vulgare) 
B hordein Q40026 15.1 12 15.1 0.156 4.96 
 D hordein Q40054 8.8 11 8.7 0.075 1.04 
 γ-hordein-3 P80198 15.6 9 15.6 0.14 4.22 
 Large subunit RuBisCO P05698 9.9 12 9.6 0.133 2.52 
 Small subunit RuBisCO Q40004 15.6 8 14.1 0.071 4.78 
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Oat (Avena sativa) Avenin P27919 12.4 8 10.8 0.12 5.68 
 11S globulin Q38779 7.2 10 7 0.061 1.03 
 12S globulin Q49257 7.5 16 7.1 0.197 1.8 
 Large subunit RuBisCO P48684 9.9 12 9.7 0.133 2.52 
 Small subunit RuBisCO Q9ZWG4 15.8 10 14.5 0.081 4.39 
Corn (Zea mays) Large subunit RuBisCO P00874 9.5 11 9.3 0.121 2.31 
 Small subunit RuBisCO P05348 13 6 11.4 0.061 4.25 
Rice (Oryza sativa subsp. 
Japonica) 
Large subunit RuBisCO P0C512 9.1 11 8.8 0.12 2.28 
 Small subunit RuBisCO P18566 15.6 7 14.1 0.071 4.75 
Sorghum (Sorghum 
vulgare) 
Large subunit RuBisCO A1E9T2 9.5 11 9.3 0.121 2.31 
 Small subunit RuBisCO C5Y519 14.2 8 13 0.083 4.36 
Soybean (Glycine 
hispida) 
Basic 7S P13917 8.4 10 8.4 0.089 2.04 
 Glycinin P04347 8.3 12 8.1 0.071 1.28 
 β-conglycinin, β-chain P25974 8.2 7 8.2 0.07 1.47 
 β-conglycinin, α-chain P13916 6.8 9 6.8 0.09 1.43 
 β-conglycinin, α’-chain P11827 5.9 9 5.7 0.068 1.01 
Quinoa (Chenopodium 
quinoa) 
RuBisCO large chain K4P448 10.9 11 10.7 0.106 2.44 
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Canola (Brassica napus) Cruciferin P11090 6.9 10 6.9 0.066 1.29 
 Napin small chain P17333 16.7 3 16.7 0.037 8.98 
 Napin large chain P17333 10.5 4 9.3 0.016 1.66 
Amaranth (Amaranthus 
hypochondriacus) 
Large subunit RuBisCO P16306 10.8 13 10.6 0.14 2.67 
Palamaria palmata 
(Rhodymenia palmata) 
50S ribosomal protein L31, 
chloroplastic 
Q5MIM5 8.2 3 8.2 0.006 0.7 
 PALPL Ribosomal protein 12 Q5MIL8 16.9 4 16.9 0.006 0.91 
 Allophycocyanin α chain M1UZ22 10 13 9.8 0.128 7.28 
 Allophycocyanin β chain M1VJV1 10.9 11 10.7 0.106 2.45 
 Phycocyanin α I2FJU0 10.8 13 10.6 0.14 2.67 
 Phycocyanin β I2FJT9 12.9 6 11.3 0.061 4.18 
 Phycoerythrin α subunit F2ZAL8 8.1 11 8.1 0.04 0.93 
 Phycoerythrin β subunit F2ZAL7 9.9 13 9.8 0.439 5.8 
 RuBisCO large chain  Q9THF8 2.2 2 2.2 0.003 0.13 
 RuBisCO small chain O98734 14.1 9 14.1 0.101 4.42 
 Small subunit RuBisCO Q9XGX5 12.9 6 11.3 0.061 4.2 
Chicken egg (Gallus 
gallus) 
Ovalbumin P01012 8.1 11 8.1 0.04 0.94 
 Ovotransferrin P02789 9.9 13 9.8 0.439 5.79 
 Ovomucoid P01005 2.2 2 2.2 0.003 0.15 
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Bovine milk (Bos taurus) αs1-casein P02662 14.1 9 14.1 0.101 4.4 
 αs2-casein P02663 13 8 11.6 0.047 1.93 
 β-casein P02666 29.9 14 23.2 0.082 3.25 
 κ-casein P02668 18.3 9 15.4 0.339 17.88 
 β-lactoglobulin P02754 34 8 25.9 0.060 3.27 
 α-lactalbumin P00711 43.9 8 34.1 0.080 5.66 
 Lactoferrin P24627 11.6 18 11.6 0.203 2.67 
 BSA P02769 7.9 10 7.9 0.062 0.93 
Bovine meat (Bos taurus) Myosin-1 Q9BE40 4.6 13 4.5 0.235 1.05 
 
Myosin regulatory light chain 
12B 
A4IF97 1.2 1 1.2 0.003 0.15 
 Actin, cytoplasmin 1 P60712 8.8 8 8 0.046 1.1 
 Collagen α-1 (III) chain P02459 10.2 11 9.6 0.539 4.37 
Pig (Sus scrofa) β-actin  Q8SPK6 10.7 6 9.5 0.021 1.12 
 Actin, α skeletal muscle P68137 8.3 7 7.5 0.044 1.05 
 Myosin light chain Q29069 6 2 5.3 0.007 0.42 
 Myosin heavy chain Q29623 6 4 5.3 0.04 2.32 
Atlantic salmon (Salmo 
salar) 
Actin, cytoplasmic 1 O42161 8.3 8 7.5 0.045 1.08 
 Myosin regulatory light chain 2 Q7ZZN0 5.3 3 4.7 0.022 1.16 
  33 
 Slow myosin heavy chain Q2HXU3 4.8 5 4.4 0.032 1.25 
 Collagen Type XI α2 A7KE05 8.2 18 8.1 0.212 1.31 
Chum salmon 
(Oncorhynchus keta) 
Type 1 collagen α2 chain Q8UUJ4 13.6 11 12.3 0.743 5.88 
 Actin Q9PVN1 8.2 7 7.4 0.044 1.05 
 β-actin J7ID80 8.6 4 7.6 0.023 1.1 
 Myosin heavy chain Q8JIP5 5.9 14 5.8 0.325 1.46 
Tuna (Thunnus 
orientalis) 
β-actin A9CM08 9.6 6 8.9 0.015 0.85 
 Myosin heavy chain-1 G9M5T1 5.3 13 5.3 0.272 1.23 
  Myosin heavy chain-2 G9M5T2 5.5 13 5.5 0.279 1.26 
 
†
 Accession number from UniProt database, data presented within this table are relative to the mature protein sequence 
‡
 The protein coverage (PC) was calculated using the Protein Coverage Summarizer based on the mature protein sequences 
("http://omics.pnl.gov/software/ProteinCoverageSummarizer.php,") 
*
 Number of peptides: actual number of unique peptide sequences taken into account in the in silico analysis 
**
 PCcorrected: corrected PC, which corresponds to the proportion of DPP-IV inhibitory peptides with an half maximal inhibitory concentration (IC50) < 2000 
μM incorporated in the model, this value was determined with an in-house algorithm 
# 
The DPP-IV inhibitory potency index (PI) was determined with an in-house algorithm 
RuBisCO: Ribulose bisphosphate carboxylase; BSA bovine serum albumin  
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Table 3 Dipeptidyl peptidase IV (DPP-IV) inhibitory potency index (PI) of κ-casein (CN) from different species 
and DPP-IV inhibitory peptide sequences taken into account in the predictive model 
 
    Species   
  Bovine Human Sheep Goat Buffalo 
Accession 
number 
 (P02668) (P07498) (P02669) (P02670) (P11840) 
PI (μM
-1
 mol
-1
) 0.339 0.038 0.355 0.335 0.342 
 ×10
6
 (μM-1 g-1) 17.89 2.11 18.52 17.51 17.90 
Peptides*  IPI - IPI IPI IPI 
  - - IPA - - 
  LPYPY - LPYPY LPYPY LPYPY 
  WQ - WQ WQ WQ 
  HL - HL HL HL 
  IP IP IP IP IP 
  VA VA VA VA VA 
  YP - YP YP YP 
  - YPYY - - - 
  - LP LP LP LP 
  VR VR VR VR VR 
  VP VP VP VP VP 
*
 Peptide sequence using the one letter amino acid code 
-: peptide sequence not found within the protein sequence 
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Figure captions  
 
Fig. 1. Regions of individual milk proteins with previously identified dipeptidyl peptidase IV 
(DPP-IV) inhibitory peptides with an half maximal inhibitory concentration (IC50) ≤ 2000 
μM. Regions of the proteins containing DPP-IV inhibitory peptides are underlined.  
 
Fig. 2. Sequence alignment of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides with (a) 
an half maximal inhibitory concentration (IC50) value < 200 μM and (b) peptides with weak 
(> 2000 μM) or no DPP-IV inhibitory properties as determined in previous studies (Gallego 
et al., 2014; Hoffmann et al., 1995; Nongonierma & FitzGerald, 2013c, 2013d; Nongonierma 
et al., 2013; Silveira et al., 2013; Uenishi et al., 2012). 
 
Fig. 3. Sequence alignment of the mature κ-casein (CN) sequence from bovine, human, 
ovine, caprine and bubaline milk. Areas highlighted correspond to the regions of the protein 
containing dipeptidyl peptidase IV (DPP-IV) inhibitory peptides with an half maximal 
inhibitory concentration (IC50) value < 200 μM. 
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αs1-casein 
RPKHPIKHQGLPQEVLNENLLRFFVAPFPEVFGKEKVNELSKDIGSESTEDQAMEDIK
QMEAESISSSEEIVPNSVEQKHIQKEDVPSERYLGYLEQLLRLKKYKVPQLEIVPNSA
EERLHSMKEGIHAQQKEPMIGVNQELAYFYPELFRQFYQLDAYPSGAWYYVPLGTQ
YTDAPSFSDIPNPIGSENSEKTTMPLW 
 
αs2-casein 
KNTMEHVSSSEESIISQETYKQEKNMAINPSKENLCSTFCKEVVRNANEEEYSIGSSSE
ESAEVATEEVKITVDDKHYQKALNEINQFYQKFPQYLQYLYQGPIVLNPWDQVKRN
AVPITPTLNREQLSTSEENSKKTVDMESTEVFTKKTKLTEEEKNRLNFLKKISQRYQ
KFALPQYLKTVYQHQKAMKPWIQPKTKVIPYVRYL 
 
β-casein 
RELEELNVPGEIVESLSSSEESITRINKKIEKFQSEEQQQTEDELQDKIHPFAQTQSLVY
PFPGPIPNSLPQNIPPLTQTPVVVPPFLQPEVMGVSKVKEAMAPKHKEMPFPKYPV
EPFTESQSLTLTDVENLHLPLPLLQSWMHQPHQPLPPTVMFPPQSVLSLSQSKVLPV
PQKAVPYPQRDMPIQAFLLYQEPVLGPVRGPFPIIV 
 
κ-casein 
QEQNQEQPIRCEKDERFFSDKIAKYIPIQYVLSRYPSYGLNYYQQKPVALINNQFLPY
PYYAKPAAVRSPAQILQWQVLSNTVPAKSCQAQPTTMARHPHPHLSFMAIPPKKNQ
DKTEIPTINTIASGEPTSTPTTEAVESTVATLEDSPEVIESPPEINTVQVTSTAV 
 
α-lactalbumin 
EQLTKCEVFRELKDLKGYGGVSLPEWVCTTFHTSGYDTQAIVQNNDSTEYGLFQI
NNKIWCKDDQNPHSSNICNISCDKFLDDDLTDDIMCVKKILDKVGINYWLAHKAL
CSEKLDQWLCEKL 
 
β-lactoglobulin 
LIVTQTMKGLDIQKVAGTWYSLAMAASDISLLDAQSAPLRVYVEELKPTPEGDLEI
LLQKWENGECAQKKIIAEKTKIPAVFKIDALNENKVLVLDTDYKKYLLFCMENSAE
PEQSLACQCLVRTPEVDDEALEKFDKALKALPMHIRLSFNPTQLEEQCHI 
 
Bovine serum albumin 
  37 
DTHKSEIAHRFKDLGEEHFKGLVLIAFSQYLQQCPFDEHVKLVNELTEFAKTCVADE
SHAGCEKSLHTLFGDELCKVASLRETYGDMADCCEKQEPERNECFLSHKDDSPDLP
KLKPDPNTLCDEFKADEKKFWGKYLYEIARRHPYFYAPELLYYANKYNGVFQECCQ
AEDKGACLLPKIETMREKVLASSARQRLRCASIQKFGERALKAWSVARLSQKFPKA
EFVEVTKLVTDLTKVHKECCHGDLLECADDRADLAKYICDNQDTISSKLKECCDKPL
LEKSHCIAEVEKDAIPENLPPLTADFAEDKDVCKNYQEAKDAFLGSFLYEYSRRHPE
YAVSVLLRLAKEYEATLEECCAKDDPHACYSTVFDKLKHLVDEPQNLIKQNCDQFE
KLGEYGFQNALIVRYTRKVPQVSTPTLVEVSRSLGKVGTRCCTKPESERMPCTEDYL
SLILNRLCVLHEKTPVSEKVTKCCTESLVNRRPCFSALTPDETYVPKAFDEKLFTFHA
DICTLPDTEKQIKKQTALVELLKHKPKATEEQLKTVMENFVAFVDKCCAADDKEAC
FAVEGPKLVVSTQTALA 
 
Lactoferrin 
APRKNVRWCTISQPEWFKCRRWQWRMKKLGAPSITCVRRAFALECIRAIAEKKAD
AVTLDGGMVFEAGRDPYKLRPVAAEIYGTKESPQTHYYAVAVVKKGSNFQLDQLQ
GRKSCHTGLGRSAGWIIPMGILRPYLSWTESLEPLQGAVAKFFSASCVPCIDRQAYP
NLCQLCKGEGENQCACSSREPYFGYSGAFKCLQDGAGDVAFVKETTVFENLPEKAD
RDQYELLCLNNSRAPVDAFKECHLAQVPSHAVVARSVDGKEDLIWKLLSKAQEKF
GKNKSRSFQLFGSPPGQRDLLFKDSALGFLRIPSKVDSALYLGSRYLTTLKNLRETAE
EVKARYTRVVWCAVGPEEQKKCQQWSQQSGQNVTCATASTTDDCIVLVLKGEAD
ALNLDGGYIYTAGKCGLVPVLAENRKSSKHSSLDCVLRPTEGYLAVAVVKKANEGL
TWNSLKDKKSCHTAVDRTAGWNIPMGLIVNQTGSCAFDEFFSQSCAPGADPKSRLC
ALCAGDDQGLDKCVPNSKEKYYGYTGAFRCLAEDVGDVAFVKNDTVWENTNGES
TADWAKNLNREDFRLLCLDGTRKPVTEAQSCHLAVAPNHAVVSRSDRAAHVKQVL
LHQQALFGKNGKNCPDKFCLFKSETKNLLFNDNTECLAKLGGRPTYEEYLGTEYVT
AIANLKKCSTSPLLEACAFLTR 
 
 
 
Fig. 1 
  38 
(a) (b)
 
Fig. 2 
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Fig. 3 
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Supplementary data 
 
Supplementary Table 1 Peptide sequences which have been found to have a dipeptidyl 
peptidase IV (DPP-IV) half maximal inhibitory concentration (IC50) > 2000 μM. 
 
Peptide sequence* Source 
VRGP (Nongonierma & FitzGerald, 2013c) 
QP (Nongonierma & FitzGerald, 2013c) 
IQP (Nongonierma & FitzGerald, 2013c) 
NP (Nongonierma & FitzGerald, 2013c) 
GP (Nongonierma & FitzGerald, 2013c) 
HQP (Nongonierma & FitzGerald, 2013c) 
ITP (Nongonierma & FitzGerald, 2013c) 
KHP (Nongonierma & FitzGerald, 2013c) 
KYP (Nongonierma & FitzGerald, 2013c) 
NSLP (Nongonierma & FitzGerald, 2013c) 
VEP (Nongonierma & FitzGerald, 2013c) 
WE (Nongonierma & FitzGerald, 2013d) 
WF (Nongonierma & FitzGerald, 2013d) 
WG (Nongonierma & FitzGerald, 2013d) 
AW (Nongonierma & FitzGerald, 2013d) 
WD (Nongonierma & FitzGerald, 2013d) 
NW (Nongonierma & FitzGerald, 2013d) 
YW (Nongonierma & FitzGerald, 2013d) 
CW (Nongonierma & FitzGerald, 2013d) 
SW (Nongonierma & FitzGerald, 2013d) 
EW (Nongonierma & FitzGerald, 2013d) 
FW (Nongonierma & FitzGerald, 2013d) 
GW (Nongonierma & FitzGerald, 2013d) 
NW (Nongonierma & FitzGerald, 2013d) 
PW (Nongonierma & FitzGerald, 2013d) 
EK (Nongonierma & FitzGerald, 2013a) 
SL (Nongonierma & FitzGerald, 2013a) 
GL (Nongonierma & FitzGerald, 2013a) 
DW (Nongonierma & FitzGerald, 2013a) 
RW (Nongonierma et al., 2013) 
VW (Nongonierma et al., 2013) 
SF (Nongonierma et al., 2013) 
IW (Nongonierma et al., 2013) 
GQ (Nongonierma et al., 2013) 
DK (Nongonierma et al., 2013) 
YY (Nongonierma & FitzGerald, 2014) 
IQY (Nongonierma & FitzGerald, 2014) 
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LIVTQTM (Silveira et al., 2013) 
ALPMHIR (Silveira et al., 2013) 
KA (Gallego et al., 2014) 
AA (Gallego et al., 2014) 
GP (Gallego et al., 2014) 
PL (Gallego et al., 2014) 
AAATP (Gallego et al., 2014) 
AAAAG (Gallego et al., 2014) 
ALGGA (Gallego et al., 2014) 
LVSGM (Gallego et al., 2014) 
ASGPINFT (Gallego et al., 2014) 
DVITGA (Gallego et al., 2014) 
SAGPN (Gallego et al., 2014) 
VPPFIQPE (Uenishi et al., 2012) 
RIQRGPR (Hoffmann et al., 1995) 
CNTKKGIAIGPG (Hoffmann et al., 1995) 
CNTRKRIRIQRGPG (Hoffmann et al., 1995) 
TEKLWVTVYYGV (Hoffmann et al., 1995) 
GGPA (Hoffmann et al., 1995) 
AAPA (Hoffmann et al., 1995) 
TKPR (Hoffmann et al., 1995) 
MKRPPGFSPFR (Hoffmann et al., 1995) 
*Peptide sequence using the one letter amino acid code 
 
 
